• Olema Pharmaceuticals held its annual shareholder meeting on June 17, 2026.
• Shareholders backed the board’s slate of director nominees, setting terms through the 2029 annual meeting.
• Shareholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-279483), on June 23, 2026, and is solely responsible for the information contained therein.